Sugi Predict

Sugi Predict / Compounds / SCHEMBL129780

SCHEMBL129780

SCHEMBL129780

CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@@H]1CN(C)C[C@H]1OC(=O)CCCCCCC/C=C\C/C=C\CCCCC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.52
▸ F7 P08709 4/20 0.52
▸ F3 P13726 4/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ PPARG P37231 3/20 0.52
▸ PPARD Q03181 3/20 0.52
▸ PPARA Q07869 3/20 0.52
▸ FABP3 P05413 3/20 0.52
▸ FFAR1 O14842 3/20 0.52
▸ PTGS1 P23219 2/20 0.52
▸ DUSP3 P51452 1/20 0.52
▸ PTPN7 P35236 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP19A1 P11511 1/20 0.52
▸ FABP4 P15090 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ GNA15 P30679 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25067389 1.00 ALDH1A1 (0.52) ALDH1A1F7F3KDM4EPPARG
SCHEMBL131816 1.00 ALDH1A1 (0.52) ALDH1A1F7F3KDM4EPPARG
SCHEMBL14759763 1.00 ALDH1A1 (0.52) ALDH1A1F7F3KDM4EPPARG
SCHEMBL14934992 1.00 ALDH1A1 (0.52) ALDH1A1F7F3KDM4EPPARG
SCHEMBL14900630 1.00 ALDH1A1 (0.52) ALDH1A1F7F3KDM4EPPARG
SCHEMBL14759872 0.96 TERT (0.49) F7F3PPARGPPARDPPARA
SCHEMBL14900515 0.96 TERT (0.49) F7F3PPARGPPARDPPARA
SCHEMBL15339452 0.96 TERT (0.49) F7F3PPARGPPARDPPARA
SCHEMBL14759875 0.96 TERT (0.49) F7F3PPARGPPARDPPARA
SCHEMBL20017932 0.93 ALDH1A1 (0.48) ALDH1A1F7F3KDM4EPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771715-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-10-03 — — US disclosed
US-11771715-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-10-03 — — US disclosed
US-11766449-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-09-26 — — US disclosed
US-11766449-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-09-26 — — US disclosed
US-20230226096-A1 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. 2023-07-20 — — US disclosed
US-20230226096-A1 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. 2023-07-20 — — US disclosed
US-11679120-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-06-20 — — US disclosed
US-11679120-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-06-20 — — US disclosed
US-20230058784-A1 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. 2023-02-23 — — US disclosed
EP-2567951-B1 CATIONIC LIPID KYOWA HAKKO KIRIN CO LTD (JP) 2018-09-19 — — EP disclosed
US-20130280305-A1 CATIONIC LIPID KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-10-24 — — US disclosed
US-20130108685-A1 CATIONIC LIPID KYOWA KIRIN CO., LTD. (JP) 2013-05-02 — — US disclosed
US-20130108685-A1 CATIONIC LIPID KYOWA KIRIN CO., LTD. (JP) 2013-05-02 — — US disclosed
EP-2567951-A1 CATIONIC LIPID Kyowa Hakko Kirin Co., Ltd. (JP) 2013-03-13 — — EP disclosed
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-17 — — US disclosed
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-17 — — US disclosed
US-20120058144-A1 LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-03-08 — — US disclosed
US-20120058144-A1 LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-03-08 — — US disclosed
WO-2011075656-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 — — WO disclosed
WO-2010054384-A1 LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11771715-B2 Circular RNA compositions and methods RTCB, HNRNPA1, HNRNPAB ALDH1A1 4484/4885F7 652/4885F3 2185/4885
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS LIPA, APOB, LIPC ALDH1A1 4338/4885F7 1103/4885F3 2384/4885
US-20120058144-A1 LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ABCB4, CETP, SGMS1 ALDH1A1 3777/4885F7 137/4885F3 503/4885
US-20130108685-A1 CATIONIC LIPID LPAR3, ACOX3, H1-3 ALDH1A1 3173/4885F7 1632/4885F3 466/4885
US-20130280305-A1 CATIONIC LIPID LPAR3, ACOX3, H1-3 ALDH1A1 3173/4885F7 1632/4885F3 466/4885
US-20230226096-A1 CIRCULAR RNA COMPOSITIONS AND METHODS RTCB, HNRNPA1, HNRNPAB ALDH1A1 4484/4885F7 652/4885F3 2185/4885
US-20230058784-A1 CIRCULAR RNA COMPOSITIONS AND METHODS RTCB, RNGTT, HNRNPAB ALDH1A1 4532/4885F7 669/4885F3 2046/4885
US-11679120-B2 Circular RNA compositions and methods RTCB, HNRNPA1, HNRNPAB ALDH1A1 4484/4885F7 652/4885F3 2185/4885
US-11766449-B2 Circular RNA compositions and methods RTCB, RNGTT, HNRNPAB ALDH1A1 4532/4885F7 669/4885F3 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.